secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001193125-24-200993
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma submits NDA to FDA for UGN-102 for low-grade intermediate-risk NMIBC
--------------------------------------------------------------------------------

- Completed NDA submission for UGN-102 to the U.S. FDA.
- UGN-102 is intended for low-grade intermediate-risk non-muscle invasive bladder cancer treatment.
- Regulatory submission marks a key milestone toward potential approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524200993/0001193125-24-200993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524200993/d834673d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer